Literature DB >> 1493844

Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin.

T O Klemsdal1, K Gjesdal, J E Bredesen.   

Abstract

19 healthy volunteers wore a nitroglycerin patch releasing 10 mg per 24 h for 2 h. Subsequently, the skin area surrounding the patch was exposed to 15 min of local heating with an infrared bulb (Group A, n = 10), or local cooling with an ice-pack (Group B, n = 9). The patch was protected by an insulating shield (Styrofoam). After 10 min of heating, the median (Walsh) plasma nitroglycerin level increased from 3.1 to 7.6 nmol.l-1. Body temperature remained constant. After 15 min of cooling the median plasma level had dropped from 2.1 to 1.4 nmol.l-1. The results demonstrate that changes in skin temperature may cause extensive short-term changes in the bioavailability of nitroglycerin. Presumably, a subcutaneous or cutaneous reservoir builds up during transdermal treatment, and changes in regional cutaneous blood flow affect the rate of drainage from the reservoir into the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493844     DOI: 10.1007/bf02284961

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Photoplethysmography. Part 1. Comparison with laser Doppler flowmetry.

Authors:  L G Lindberg; T Tamura; P A Oberg
Journal:  Med Biol Eng Comput       Date:  1991-01       Impact factor: 2.602

Review 2.  The promise of transdermal drug delivery.

Authors:  W S Nimmo
Journal:  Br J Anaesth       Date:  1990-01       Impact factor: 9.166

3.  Increased uptake of transdermal glyceryl trinitrate during physical exercise and during high ambient temperature.

Authors:  T F Barkve; K Langseth-Manrique; J E Bredesen; K Gjesdal
Journal:  Am Heart J       Date:  1986-09       Impact factor: 4.749

4.  Pharmacological activity of the dinitrate metabolites of nitroglycerin following their oral administration to healthy volunteers.

Authors:  M Gumbleton; L Z Benet
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

5.  The effects of moderate sustained exercise on the pharmacokinetics of nitroglycerine.

Authors:  S Weber; D de Lauture; E Rey; T Darragon; J P Severins; A Ditisheim; G Olive; M Degeorges
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

6.  Difference in nitroglycerin dose-response in the venous and arterial beds.

Authors:  P R Imhof; B Ott; P Frankhauser; L C Chu; J Hodler
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

7.  New transdermal and transmucosal nitroglycerin delivery systems in patients with ischaemic heart disease.

Authors:  V I Metelitsa; V K Piotrovskii; O S Ryabokon; S V Blagodatskikh
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Pharmaceutical considerations of transdermal nitroglycerin delivery: the various approaches.

Authors:  Y W Chien
Journal:  Am Heart J       Date:  1984-07       Impact factor: 4.749

9.  Human pharmacological studies of a new transdermal system containing nitroglycerin.

Authors:  P Müller; P R Imhof; F Burkart; L C Chu; A Gérardin
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects.

Authors:  E F McNiff; A Yacobi; F M Young-Chang; L H Golden; A Goldfarb; H L Fung
Journal:  J Pharm Sci       Date:  1981-09       Impact factor: 3.534

View more
  15 in total

1.  Cutaneous vasomotor reactions in response to controlled heat applied on various body regions of healthy humans: evaluation of time course and application parameters.

Authors:  Parisa Gazerani; Lars Arendt-Nielsen
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-07

2.  Direct vasodilation by transdermal administration of nitroglycerin: preliminary, randomized, placebo-controlled trial of nitroglycerin skin spray for premedication before artery puncture.

Authors:  Keizo Tanitame; Chihiro Tani; Yuko Nakamura; Wataru Yamasaki; Masaki Ishikawa; Hideaki Kakizawa; Shuji Date; Kazuo Awai
Journal:  Jpn J Radiol       Date:  2012-05       Impact factor: 2.374

3.  The effect of topical capsaicin-induced sensitization on heat-evoked cutaneous vasomotor responses.

Authors:  Thomas A Nielsen; Larissa Bittencourt da Silva; Lars Arendt-Nielsen; Parisa Gazerani
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-09-10

4.  Novel pharmacokinetic modelling of transdermal nitroglycerin.

Authors:  B Auclair; G Sirois; A H Ngoc; M P Ducharme
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

5.  The experimental evaluation and molecular dynamics simulation of a heat-enhanced transdermal delivery system.

Authors:  Daniel P Otto; Melgardt M de Villiers
Journal:  AAPS PharmSciTech       Date:  2012-12-11       Impact factor: 3.246

Review 6.  Heat exposure and drugs. A review of the effects of hyperthermia on pharmacokinetics.

Authors:  J Vanakoski; T Seppälä
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

7.  Physical exercise increases plasma concentrations of nicotine during treatment with a nicotine patch.

Authors:  T O Klemsdal; K Gjesdal; K Zahlsen
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

8.  Effect of Controlled Heat Application on Topical Diclofenac Formulations Evaluated by In Vitro Permeation Tests (IVPT) Using Porcine and Human Skin.

Authors:  Sherin Thomas; Soo Hyeon Shin; Dana C Hammell; Hazem E Hassan; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2020-02-07       Impact factor: 4.200

Review 9.  Clinical pharmacokinetics of nitrates.

Authors:  M G Bogaert
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 10.  Potential interactions between exercise and drug therapy.

Authors:  Thomas L Lenz; Nancy J Lenz; Michele A Faulkner
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.